Erik Manting
Chief Executive Officer presso MENDUS AB
Patrimonio netto: 60 707 $ in data 31/03/2024
Profilo
Erik Manting is the founder of Bioentrepreneur BV, which was founded in 2017.
He is currently an Independent Director at TransCode Therapeutics, Inc. since 2020, the Chief Executive & Business Officer at Mendus AB since 2021, and a Member-Supervisory Board at Synerkine Pharma BV since 2019.
Dr. Manting's former positions include being the Chief Executive Officer at DCPrime BV from 2017 to 2020,.
the Executive Director-Life Sciences & Healthcare at Kempen & Co. NV from 2012 to 2017, and an Analyst at Rabo Securities NV in 2005.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
MENDUS AB
0.21% | 31/12/2022 | 1 442 312 ( 0.21% ) | 60 707 $ | 31/03/2024 |
13/12/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Erik Manting
Società | Posizione | Inizio |
---|---|---|
MENDUS AB | Chief Executive Officer | 16/03/2021 |
TRANSCODE THERAPEUTICS, INC. | Director/Board Member | 20/12/2020 |
Synerkine Pharma BV
Synerkine Pharma BV Miscellaneous Commercial ServicesCommercial Services Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands. | Director/Board Member | 01/03/2019 |
Precedenti posizioni note di Erik Manting
Società | Posizione | Fine |
---|---|---|
DCPrime BV
DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Chief Executive Officer | 01/12/2020 |
Kempen & Co. NV
Kempen & Co. NV Financial ConglomeratesFinance Kempen & Co. NV provides financial services to professional investors. The company's clients include institutional investors, companies, financial institutions, public & semi-public institutions, foundations and high-net-worth private clients. The company was founded in July 1903 by A. J. Kempen and M. D. de Lange and is headquartered in Amsterdam, The Netherlands. | Corporate Officer/Principal | 01/09/2017 |
Rabo Securities NV | Analyst-Equity | 14/09/2005 |
Bioentrepreneur BV | Founder | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
MENDUS AB | Health Technology |
TRANSCODE THERAPEUTICS, INC. | Health Technology |
Aziende private | 5 |
---|---|
Kempen & Co. NV
Kempen & Co. NV Financial ConglomeratesFinance Kempen & Co. NV provides financial services to professional investors. The company's clients include institutional investors, companies, financial institutions, public & semi-public institutions, foundations and high-net-worth private clients. The company was founded in July 1903 by A. J. Kempen and M. D. de Lange and is headquartered in Amsterdam, The Netherlands. | Finance |
Rabo Securities NV | Finance |
DCPrime BV
DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Health Technology |
Synerkine Pharma BV
Synerkine Pharma BV Miscellaneous Commercial ServicesCommercial Services Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands. | Commercial Services |
Bioentrepreneur BV |
- Borsa valori
- Insiders
- Erik Manting